Indexed on: 01 Dec '17Published on: 30 Nov '17Published in: Journal of Global Antimicrobial Resistance
Publication date: Available online 27 November 2017 Source:Journal of Global Antimicrobial Resistance Author(s): Wenrui Gu, Qiong Yu, Cuixiang Yu, Shujuan Sun Objective The treatment of azoles-resistant Candida albicans infections continues to pose significant challenges. With limited options of licensed agents, the drug’s combination turns out to be a practical way. In our previous studies, minocycline/fluconazole (MINO/FLC) and doxycycline/fluconazole (DOXY/FLC) combinations shown synergistic effect in vitro. It is necessary to explore appropriate dosage, potential toxicity and in vivo efficacy. Methods The Galleria mellonella infection model was employed to study the in vivo efficacy of MINO/FLC and DOXY/FLC by survival analysis, quantification of C. albicans CFU/mL, and histological analysis. Results The survival rates of G. mellonella larvae infected with lethal doses of C. albicans increased significantly when drug combination was given compared to fluconazole treatment alone. The fungal burden reduced by almost 4-fold and histopathology study showed that fewer infected areas in larvae were observed and the destructive degree was slighter when larvae were exposed to combined drugs. Conclusions The findings suggest that the combination of tetracycline and fluconazole has antifungal activity against azoles-resistant Candida albicans in vivo. This is in agreement with several previous in vitro studies and provides preliminary in vivo evidence that such a combination might be useful therapeutically.